TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05534672

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rapamycin
Description: Rapamycin in liquid administered orally

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo in liquid administered orally
Study: NCT05634993

Intervention type: OTHER
Intervention: Assessment
Description: Assessment of disability level and trunk control
Study: NCT05167006

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: routine physical therapy
Description: Each participant will receive his/her arms training therapy. Only one participant per therapist, with or without caregiver observation. Consisting of many purposeful kinesthetic activities such as Graded pinch exercise, Bimanual placing cone, Arm bicycling, Shoulder curved arch, Double-curved arch, Block-stacking, Skateboard-supported arm sliding exercises on a tabletop, Putty kneading, Pegboard exercise, Picking up a ball and putting it into a basket, Plastic cone stacking. Therapists can offer passive, active-assistive, or active training, as deemed appropriate to the patient's ability

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Perfetti's method
Description: . Only one participant per therapist, with or without caregiver observation. Participant will be blindfolded during the exercises and asked to focus on sensing the position of the limb. The therapist will passively move the shoulder, elbow, wrist, or fing
Study: NCT05069870

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SKLB1028
Description: SKLB1028, capsule, oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SKLB1028
Description: SKLB1028, capsule, oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SKLB1028
Description: SKLB1028, capsule, oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Itraconazole, capsule, oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemfibrozil
Description: Gemfibrozil, capsule, oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampicin
Description: Rifampicin, capsule, oral
Study: NCT04397003

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Neoantigen DNA vaccine
Description: All study injections will be given intramuscularly using an integrated electroporation device (TDS-IM system, PapiVax Biotech). At each vaccination time point, patients will receive two injections of the neoantigen DNA vaccine, one injection into each deltoid or lateralis.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: -Supplied by AstraZeneca
Study: NCT04954651

Intervention type: BIOLOGICAL
Intervention: Approved vaccines against Sars-Cov2
Description: Subjects who voluntarily are vaccinated against Sars-Cov-2 with any of the approved vaccines by EU
Study: NCT06374043

Intervention type: DRUG
Group type: OTHER
Intervention: Dapagliflozin 10mg Tab
Description: Oral administration

Intervention type: DRUG
Group type: OTHER
Intervention: Dapagliflozin 10mg Tab
Description: Oral administration

Intervention type: DRUG
Group type: OTHER
Intervention: Dapagliflozin 10mg Tab
Description: Oral administration

Intervention type: DRUG
Group type: OTHER
Intervention: Dapagliflozin 10mg Tab
Description: Oral administration

Intervention type: DRUG
Group type: OTHER
Intervention: Dapagliflozin 10mg Tab
Description: Oral administration

Intervention type: DRUG
Group type: OTHER
Intervention: Dapagliflozin 10mg Tab
Description: Oral administration

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: Oral administration

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: Oral administration

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: Oral administration

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: Oral administration
Study: NCT04397003

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TDS-IM v2.0 Device
Description: -Integrated electroporation administration system

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral blood draws
Description: -Pre-treatment, Cycle 2 Day 1, Cycle 3 Day 1, Cycle 4 Day 1, Vaccine Day 1, Vaccine Day 29, Vaccine Day 85, Vaccine Day 141, on even numbers of cycles for durvalumab for one year following completion of vaccine
Study: NCT04923984

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Embolization of the middle meningeal artery
Description: embolization of the middle meningeal artery with an embolic agent.
Study: NCT04459507

Intervention type: OTHER
Intervention: No intervention
Description: No intervention will be administered as a part of this study. Both retrospective and prospective data will be collected. The retrospective data will be collected through participant charts and prospective data will be collected in accordance with clinical practice at the participant's clinic visits.
Study: NCT05417516

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Whole Breast Irradiation (WBI)
Description: The dose fractionation and prescription is 26Gy in 5 fractions to the PTV once per day over 5-7 days (due to holiday weekends up to 8 days will be acceptable).
Study: NCT06374043

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: Oral administration
Study: NCT05417516

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Partial Breast Irradiation (PBI)
Description: The dose fractionation and prescription is 26Gy in 5 fractions to the PTV prescribed at the isocentre of the treatment fields treated once per day over 5-7 days (due to holiday weekends up to 8 days will be acceptable).
Study: NCT05710406

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Encorafenib
Description: Given PO
Study: NCT06044896

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Supine Positioning
Description: The participant will be guided to the Multicare bed and will be positioned supine with the headboard not tilted. At this point, the participant will already have the EIT electrode belt and head, trunk and lower limb cushions around it, providing stability. After the participant has been correctly positioned, ventilatory monitoring will begin using the EIT. The environment must be fully controlled, that is, with adequate lighting, all collection members in silence, as well as the devices in the place, air-conditioned environment, without exposing the participant to heat or cold. Before starting the collection, the volunteer will be asked to try not to sleep or talk, making it clear that any discomfort can be reported at any time. To keep the volunteer awake, visual and sound stimuli can be performed. Furthermore, if you cough or sigh, the collection will restart. The intervention will last 5 minutes and will be repeated twice, with intervals between body lateralization.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Body Lateral Positioning
Description: The participant will start from the bench press to the 30-degree lateral position. The cushions placed at the beginning of the collection will provide stability so that the inclination does not compromise the correct positioning of the participant, preventing them from sliding on the bed. Furthermore, it is also a safety measure for the participant. The environment will be controlled throughout the intervention and visual and sound effects will also be performed in lateral positioning. The volunteer will remain in this position for five minutes and shortly after will be placed in the supine position again. To start the protocol for the second and final time, the participant will have a washout time of thirty minutes.
Study: NCT04909905

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Standard enteral nutrition
Description: Standard enteral nutrition according to ICU nutrition protocol for 7 days

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Glutamine
Description: Intravenous glutamine supplementation to enteral nutrition in a dose of dose of glutamine of 0.4 g/kg/day for 7days
Study: NCT05710406

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Given IV
Study: NCT06374043

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: Oral administration

Intervention type: DEVICE
Group type: OTHER
Intervention: Withings BPM Connect
Description: CE marked and clinically validated blood pressure monitor. Clinical trial results are within the margin of acceptance defined by the internationally recognized evaluation standard of blood pressure monitors ANSI/AAMI/ISO 81060-2:2013, EN ISO 81060-2:2014, developed by the European Society of Hypertension, British Hypertension Society and Association for the Advancement of Medical Instrumentation/American Heart Association.~Blood pressure will be measured by the participants once daily on 28 days. Three consecutive measurements are taken.

Intervention type: DEVICE
Group type: OTHER
Intervention: Withings BPM Connect
Description: CE marked and clinically validated blood pressure monitor. Clinical trial results are within the margin of acceptance defined by the internationally recognized evaluation standard of blood pressure monitors ANSI/AAMI/ISO 81060-2:2013, EN ISO 81060-2:2014, developed by the European Society of Hypertension, British Hypertension Society and Association for the Advancement of Medical Instrumentation/American Heart Association.~Blood pressure will be measured by the participants once daily on 28 days. Three consecutive measurements are taken.
Study: NCT05710406

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Patient Observation
Description: Undergo observation per usual care
Study: NCT05621759

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Nitrogen mustard alkylating agent produced by Bristol-Myers Squibb.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abatacept
Description: Calcineurin-inhibitor produced by Astellas.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Selective T cell co-stimulation modulator produced by Bristol-Myers Squibb.
Study: NCT04605809

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: combined motor and cognitive training
Description: The combined motor and cognitive training group will receive physical fitness training under sitting and standing, walking training while sequentially or simultaneously perform cognitive training for 45 minutes per session, 3 times a week for 4 weeks.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: motor training alone
Description: The motor training alone group will receive the same set of physical fitness training while sitting, standing, and walking as the combined motor and cognitive training group for 45 minutes per session, 3 times a week for 4 weeks.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: cognitive training alone
Description: The cognitive training alone group will receive the same set of cognitive training while sitting as the combined motor and cognitive training group for 45 minutes per session, 3 times a week for 4 weeks.
Study: NCT05088252

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desflurane
Description: After induction, anesthesia will be maintained with 0.7-1.0 MAC desflurane and 0.05-0.3 μg/kg/min remifentanil.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: After induction, anesthesia will be maintained with 4-6mg/kg/h propofol and 0.05- 0.3 μg/kg/min remifentanil.
Study: NCT06260488

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Endovascular surgery
Description: routine endovascular surgery and FPAS harvesting from amputated limbs to evaluate the technical feasibility of histological segmentation by the FPAS algorithm from CT
Study: NCT05728099

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Expiratory muscle strength training + SpiroGym application
Description: Participants will performe an intensive home-based expiratory muscle training programme using an Expiratory Muscle Trainer (EMST150; Aspire Products, LLC, United States), which provide a pressure- threshold range from 30 to 150 cmH20. EMST therapy sessions will be completed at home on 5 days of the patients choosing per week. Participants will be instructed to perform five sets of five forceful expirations coupled with SpiroGym app. per training session for 8 weeks (intensive training period). For another 16 weeks (maintenance period) participants will be instructed to perform, at least twice per week, five sets of five forceful expirations coupled with SpiroGym app. per training session .

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Expiratory muscle strength training
Description: Participants will performe an intensive home-based expiratory muscle training programme using an Expiratory Muscle Trainer (EMST150; Aspire Products, LLC, United States), which provide a pressure- threshold range from 30 to 150 cmH20. EMST therapy sessions will be completed at home on 5 days of the patients choosing per week. Participants will be instructed to perform five sets of five forceful expirations per training session for 8 weeks (intensive training period). For another 16 weeks (maintenance period) participants will be instructed to perform, at least twice per week, five sets of five forceful expirations per training session. Participants will be given the practice log to track training adherence.
Study: NCT04891640

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard TNFi Therapy
Description: Participants randomly assigned to this arm will continue taking their TNFi medication as currently prescribed.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TNFi fixed longer dosing intervals
Description: Participants randomly assigned to this arm will increase the time between TNFi medication doses.~* Adalimumab- from every 2 to 3 weeks~* Certolizumab- from every 2 to 4 weeks~* Etanercept- from every 1 to 2 weeks~* Golimumab- from every 4 to 6 weeks~* Infliximab- from baseline to baseline + 2 weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stop TNFi treatment
Description: Participants randomly assigned to this arm will stop TNFi medication.
Study: NCT05519592

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine injection
Description: Intramuscular ropivacaine injection (gluteus maximus and rectus femoris)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium Chloride Injection
Description: Intramuscular sodium chloride injection (gluteus maximus and rectus femoris)
Study: NCT05761795

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IVMED 85
Description: Eye drop

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IVMED 85
Description: Eye drop

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IVMED 85
Description: Eye drop

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IVMED 85
Description: Eye drop

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IVMED 85
Description: Eye drop

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IVMED 85
Description: Eye drop

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo eye drop

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo eye drop

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo eye drop

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo eye drop
Study: NCT00012948

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Telephone Care
Study: NCT04277325

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Emotionally Focused Therapy
Description: Emotionally Focused Couples Therapy (EFT) is an empirically supported, attachment-based model of couples therapy that combines experiential, systems, and attachment theories with the goal of fostering the development of safe contact, accessibility, and responsiveness in both partners.
Study: NCT05986942

Intervention type: DRUG
Intervention: Fentanyl
Description: In Group dex, dexmedetomidine infusion will be administered to the patient during the operation. Fentanyl bolus dose will be administered during anesthesia induction in group Fen.

Intervention type: DRUG
Intervention: Dexmedetomidine
Description: In Group dex, dexmedetomidine infusion will be administered to the patient during the operation. Fentanyl bolus dose will be administered during anesthesia induction in group Fen.
Study: NCT04086732

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: High-frequency electrical stimulation
Description: High-frequency stimulation will be applied on the volar forearm (6-10 cm distal to the cubital fossa). To avoid any confounding effect of handedness, the arm onto which HFS will be applied twice (dominant vs nondominant) will be counterbalanced across participants. HFS will consist of 12 trains of 42 Hz electrical pulses lasting 1 s each. The time interval between each train will be 10 s. The intensity of stimulation will be milliampere. Electrical pulses will be delivered to the skin using a specifically-designed electrode designed: the cathode consists of 16 blunt stainless-steel pins with a diameter of 0.2 mm protruding 1 mm from the base. The 16 pins are placed in a circle with a diameter of 10 mm. The anode consists of a surrounding stainless-steel ring having an inner diameter of 22 mm and an outer diameter of 40 mm. This procedure induces secondary pinprick hyperalgesia (an increase in pinprick sensitivity in a large area of the skin).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: High-frequency electrical stimulation
Description: High-frequency stimulation will be applied on the volar forearm (6-10 cm distal to the cubital fossa). To avoid any confounding effect of handedness, the arm onto which HFS will be applied twice (dominant vs nondominant) will be counterbalanced across participants. HFS will consist of 12 trains of 42 Hz electrical pulses lasting 1 s each. The time interval between each train will be 10 s. The intensity of stimulation will be milliampere. Electrical pulses will be delivered to the skin using a specifically-designed electrode designed: the cathode consists of 16 blunt stainless-steel pins with a diameter of 0.2 mm protruding 1 mm from the base. The 16 pins are placed in a circle with a diameter of 10 mm. The anode consists of a surrounding stainless-steel ring having an inner diameter of 22 mm and an outer diameter of 40 mm. This procedure induces secondary pinprick hyperalgesia (an increase in pinprick sensitivity in a large area of the skin).
Study: NCT04799561

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multimodal Teleprehabilitation
Description: Exercise Prescription: patients will be instructed on how to perform aerobic exercise (5 times/week: minimum 30-minute/day) and resistance training (3 times/week: 2-3 sets of 6-8 exercises repeated 8-12 times) at home. Exercise counseling will be weekly, using the video-conferencing application (Zoom).~Nutrition: nutritional status and dietary intake will initially be assessed by the nutritionist using zoom. All patients will receive daily whey protein supplements. Special precautions will be considered if patients have specific medical conditions.~Psychosocial intervention: Patients will have access to 1.5 hours of mental relaxation and coping mechanisms session within the first week of enrolment, using Zoom.~Smoking Cessation: Patients with smoking habits will meet with a respiratory specialist using Zoom, who will establish recommendations and contact the physician for the recommended smoking cessation protocol.~More counseling sessions will be provided as needed.
Study: NCT05812391

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: test
Description: the treatment start with supra-gingival erythritol powerder air polishing followed by sub-gingival erythritol powerder air polishing,supra-gingival debridement and sub-gingival debridement

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conventional
Description: the treatment start with supra-gingival debridement followed by sub-gingival debridement then finished with polishing paste
Study: NCT06353776

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conjunctival biopsy after micropulse transscleral laser therapy
Description: During MicroPulse TLT, all patients received periocular anesthesia, with an injection of 5 to 10 ml of Lidocaine (Xylocaine 5mg/ml ®) to achieve complete anesthesia.~The investigators employed the 810 nm Cyclo G6® Laser in its MicroPulse® mode (Iridex Corporation, Mountain View, CA, USA) and delivered laser energy to the eye using the second-generation MicroPulse P3® probe (Iridex Corporation, Mountain View, CA, USA). The laser was calibrated to generate a power output of 2500 mW, and a MicroPulse duty cycle of 31.3%. The curved end of the probe's footplate (bunny ears) was positioned 0.5 to 1 mm away from the corneoscleral limbus, maintaining a perpendicular orientation to the eyeball.~Following the laser therapy, an immediate conjunctival biopsy measuring 2 \* 2 mm and avoiding the laser-treated region was performed.
Study: NCT05337397

Intervention type: PROCEDURE
Intervention: Laser ablation
Description: Laser ablation of non-Muscle invasive bladder tumors in outpatient settings.
Study: NCT05373056

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Scapular program
Description: the patient will be in prone. With the elbow extended, begin by raising the shoulder above the head, keeping the upper extremity in line with the fibers of the lower trapezius. The participant will then remain pronated with the elbow flexed at 90 degrees and the shoulder abducted and externally rotated. Starting from this position, you should exert the force towards external rotation and then return to internal rotation. For the last exercise, the subject will be placed in a standing position holding the elastic band with one hand while the other end will fix it to the ground, while stepping on it with the foot. You will start the movement with a shoulder elevation in the plane of the scapula above 120 degrees and then perform the eccentric returning to the starting position.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Conventional program
Description: They will be performing a combination of concentric-eccentric type contractions adding an isometric contraction
Study: NCT05163015

Intervention type: OTHER
Intervention: Data collection
Description: Description: quality of life assessment

Intervention type: OTHER
Intervention: Data collection
Description: Description: quality of life assessment